Detection of bacterial endotoxin in paclitaxel liposome

doi:10.5246/jcps.2018.06.044

Abstract

Abstract:

Based on current research, there are three technologies during the test of bacterial endotoxin of liposomes: (1) extraction of bacterial endotoxin from liposomes; (2) addition of bacterial endotoxin in the process of recovery test; and (3) elimination of the interference factors from drugs and excipients. In the present study, we pointed out that the key technologies to test bacterial endotoxin from paclitaxel liposome included following steps: extraction of bacterial endotoxins from ethanol-dissolved liposomes; preparation of positive control of recovery solution by adding 0.01 mL standard endotoxins in 1 mL liposome ethanol solution; and the use of 0.5% human albumin to eliminate the interference from detection, and accurate detection of the bacterial endotoxin of liposomes.

Key words: Bacterial endotoxin test, Paclitaxel, Liposome, Drug delivery system

CLC Number:

R917

Supporting:

Yusheng Pei, Tong Cai, Guolai Zhang, Chen Chen, Hua Gao. Detection of bacterial endotoxin in paclitaxel liposome[J]. Journal of Chinese Pharmaceutical Sciences, 2018, 27(6): 436-441.

References

[1] Pei, Y.S.; Cai, T.; Gao, H.; Tan, D.J.; Zhang, Y.C.; Zhang, G.L. Comparison of result judgment algorithm of test for interfering factors in the bacterial endotoxins test among Chinese, Japanese, European, American, and Indian pharmacopeias. Chin. Med. J. 2014, 127, 2784-2788.

[2] Paul, H.; Donna, C.L.; Robert, A.R.; Frank, P.M.; Craig. F.; Andrew, J. The Release and Detection of Endotoxin from Liposomes. Anal. Biochem. 1997, 250, 139-146.

[3] Zhang, Z.Y.; Zhang, X.P.; Ma, Y.P.; Tang, L.M. Determination of Bacterial Endotoxins in Paclitax el Liposomes. Chin. J. Pharm. 2001, 32, 266-268.

[4] Wilmar, C.; Klaus, B.; Ulrich, Z.; Kishore, R.; Tarik, K.; Friedrich, V.W. Biophysical Analysis of Lipopolysaccharide Formulations for an Understanding of the Low Endotoxin Recovery (LER) Phenomenon. Int. J. Mol. Sci. 2017, 18, 2737-2752.

[5] Masakazu, T. Factors Affecting Reduction of Reference Endotoxin Standard Activity Caused by Chelating Agent/Detergent Matrices: Kinetic Analysis of Low Endotoxin Recovery. PDA J. Pharm. Sci. Tech. 2017, 71, 478-487.

[6] Reich, J.; Lang, P.; Grallert, H.; Motschmann, H. Masking of endotoxin in surfactant samples: effects on Limulus-based detection systems. Biologicals. 2016, 44, 417-422.
[7] Bolden, J.S.; Warburton, R.E.; Phelan, R.; Murphy, M.; Smith, K.R.; De Felippis, M.R.; Chen, D. Endotoxin recovery using limulus amebocyte lysate (LAL) assay. Biologicals. 2016, 44, 434-440.
[8] Terwogt, J.M.; Nuijen, B.; Ten.; Huinink, W.W.; Beijnen, J.H. Alternative formulations of paclitaxel. Cancer Treat. Rev. 1997, 23, 87-95.

[9] Sharma, A.; Straubinger, R. Novel taxol formulations: Preparation and characterization of tax o l containing liposomes. Pharm. Res. 1994, 11, 889-896.

[10] Lin, L.; Pan, W.; Guan, Q.M. Study on bacterial endotoxin test of amphotericin B liposome for injection. J. Guangdong Pharm. Univ. 2011, 27, 274-276.

[1]	Kai Li, Bingjie Tang, Xinlong Chai, Yang Ping, Lihong Wang, Jin Su. Sialic acid-functionalized targeted drug delivery systems: advances in tumor and inflammation therapy by binding to Siglecs or selectin receptors [J]. Journal of Chinese Pharmaceutical Sciences, 2023, 32(10): 773-795.
[2]	Yajie Liu, Yu Wang, Jiajia Li, Xiaoqing Xu, Xinru Li. Preparation and evaluation of doxorubicin-luminespib co-loaded multivesicular liposomes [J]. Journal of Chinese Pharmaceutical Sciences, 2021, 30(9): 736-742.
[3]	Dakuan Wang, Bo Peng, Mengmeng Qin, Minghui Li, Ge Song, Bing He, Hua Zhang, Wenbing Dai, Qiang Zhang, Xiangbao Meng, Huan Meng, Xueqing Wang. Integrated combination delivery of IDO inhibitor and paclitaxel for cancer treatment [J]. Journal of Chinese Pharmaceutical Sciences, 2021, 30(1): 1-16.
[4]	Qi Liu, Leqi Wang, Xinping Hu, Chuhang Zhou, Yingwei Tang, Yining Ma, Xiaoxiao Wang, Yan Liu. Fabrication of deoxycholic acid-modified polymeric micelles and their transmembrane transport [J]. Journal of Chinese Pharmaceutical Sciences, 2021, 30(1): 17-26.
[5]	Jiaxing Wang, Yu Wang, Jiahui Mou, Xiaomeng Wei, Mengya Yin, Yajie Liu, Jiajia Li, Xinru Li. Decoration of bacterial outer membrane vesicles with liposomes [J]. Journal of Chinese Pharmaceutical Sciences, 2019, 28(8): 571-578.
[6]	Yitian Du, Lu Zhang, Yin Zhan, Xinyu Chai, Kaisen Li, Xianrong Qi. Interferon-liposomes prepared to make macroglia maintain M1 phenotype [J]. Journal of Chinese Pharmaceutical Sciences, 2019, 28(7): 476-483.
[7]	Bo Deng, Wei Cui, Shuang Ma, Xiaona Liu, Zhan Zhang, Baiyi Yan, Kun Chen, Ying Xie. Molecular basis for rational construction of RVGP modified liposomal delivery system targeting to brain [J]. Journal of Chinese Pharmaceutical Sciences, 2019, 28(7): 484-501.
[8]	Yajie Yin, Xiaofei Zhang, Zheng Cui, Wei Qu, Bing He, Wenbing Dai, Hua Zhang, Xueqing Wang, Qiang Zhang. In vitro dissolution and oral bioavailability study of fenofibrate nanomatrix system prepared by hot-melt extrusion [J]. Journal of Chinese Pharmaceutical Sciences, 2019, 28(5): 329-338.
[9]	Yanli Hao, Ting Zhong, Ruo Du, Hua Zhang, Bilin Liu, Xuan Zhang. The cellular uptake and anti-tumor activity of conjugated linoleic acid-paclitaxel-loaded iRGD-modified lysolipid-containing thermosensitive liposomes [J]. Journal of Chinese Pharmaceutical Sciences, 2019, 28(2): 121-133.
[10]	Wenxi Zhang, Guanghua Peng, Maoyuan Song, Jiaxing Wang, Mengya Yin, Jiajia Li, Yajie Liu, Yuanyuan Zhang, Xinru Li. Preparation and evaluation of liposomal clarithromycin with antimicrobial effect [J]. Journal of Chinese Pharmaceutical Sciences, 2018, 27(6): 408-414.
[11]	Maoyuan Song, Yuanyuan Zhang, Wenxi Zhang, Guanghua Peng, Jiaxing Wang, Mengya Yin, Jiajia Li, Yajie Liu, Xinru Li. Preparation, characterization and evaluation of multi-component-loaded liposomes containing Tat-TOS, phospholipase D inhibitor and doxorubicin [J]. Journal of Chinese Pharmaceutical Sciences, 2018, 27(5): 332-341.
[12]	Yingzi Bu, Limin Mu, Lei Liu, Wanliang Lu. Construction of folate-conjugated epirubicin liposomes for enhancing the cellular uptake and the co-localization with nuclei of invasive breast cancer cells [J]. Journal of Chinese Pharmaceutical Sciences, 2018, 27(4): 229-240.
[13]	Jingying Zhang, Qian Luo, Jiarui Xu, Jing Bai, Lei Liu, Limin Mu, Yan Yan, Wanliang Lu. A derivatization method to improve the assay of salinomycin sodium and its application in the liposomal formulation [J]. Journal of Chinese Pharmaceutical Sciences, 2018, 27(2): 75-81.
[14]	Jiongxi Lei, Shuangchen Cong, Maoyuan Song, Wenxi Zhang, Guanghua Peng, Yuanyuan Zhang, Mengya Yin, Jiaxing Wang, Jiajia Li, Xinru Li. Preparation, characterization and evaluation of liposomal doxorubicin and harmine that show synergistic activity in vitro [J]. Journal of Chinese Pharmaceutical Sciences, 2017, 26(9): 666-674.
[15]	Xiaoyou Qu, Yang Zou, Yao Jin, Yuanhang Zhou, Ziqi Wang, Chuyu He, Yunqiang Deng, Xinru Li, Yanxia Zhou, Yan Liu. Preparation and in vitro characterization of paclitaxel-loaded pH-responsive polymeric micelles based on poly(2-ethyl-2-oxazoline)-vitamin E succinate [J]. Journal of Chinese Pharmaceutical Sciences, 2017, 26(8): 582-588.